PA
XERS icon

Profund Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Profund Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
32,711
-8,422
-20% -$53.8K 0.01% 899
2026
Q1 		$239K Buy
41,133
+2,186
+6% +$14.5K 0.01% 916
2025
Q4 		$306K Buy
38,947
+12,383
+47% +$97.5K 0.01% 859
2025
Q3 		$216K Sell
26,564
-15,516
-37% -$103K 0.01% 937
2025
Q2 		$197K Buy
42,080
+21,888
+108% +$100K 0.01% 911
2025
Q1 		$111K Sell
20,192
-2,777
-12% -$11.2K ﹤0.01% 945
2024
Q4 		$77.9K Buy
22,969
+227
+1% +$730 ﹤0.01% 1084
2024
Q3 		$64.8K Sell
22,742
-1,978
-8% -$5.08K ﹤0.01% 1125
2024
Q2 		$55.6K Sell
24,720
-3,655
-13% -$7.37K ﹤0.01% 1065
2024
Q1 		$62.7K Buy
+28,375
New +$73.4K ﹤0.01% 1140

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Profund Advisors's XERS Position: Q2 2026 in Review

Profund Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 20% in Q2 2026, selling an estimated $53.8K and leaving 32,711 shares worth $259K. The position accounts for 0.01% of the portfolio, ranked #899.

Profund Advisors first reported a position in XERS in Q1 2024 and has held it in 10 quarters since. The position peaked at $306K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Profund Advisors held 32,711 shares of Xeris Biopharma Holdings worth $259K as of Q2 2026.
  • Profund Advisors sold 8,422 Xeris Biopharma Holdings shares in Q2 2026, an estimated $53.8K.
  • Xeris Biopharma Holdings made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #899 holding.
  • Profund Advisors first reported a position in Xeris Biopharma Holdings in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's Xeris Biopharma Holdings position peaked at $306K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.